Yuejuan C. Cheng
Peking Union Medical College Hospital, Peking Union Medical College
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications
Beyond tumor tracing: physiological uptake of sympathetic ganglia on somatostatin receptor PET/CT - prevalence, patterns, and biological rationale.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 19, 2026
Stable Disease Achieved with Sequential Immunochemotherapy and Anti-Angiogenic TKI in Recurrent Metastatic Hidradenocarcinoma: A Case Report and Literature Review.
Journal: Oncology research
Published: February 10, 2026
Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study.
Journal: Signal transduction and targeted therapy
Published: November 21, 2025
Preclinical and First-in-Human Study of Carbonic Anhydrase IX-Targeting Theranostic Pair, [68Ga]Ga/[177Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 04, 2025
Treatment of metastatic pancreatic cancer with concurrent BRAF V600E mutation and germline BRCA2 mutation: a case report.
Journal: Chinese clinical oncology
Published: October 13, 2025
Dynamic distribution and clearance of 99mTc-DTPA in brain extracellular space
Journal: Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
Published: June 13, 2025
S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure.
Journal: Therapeutic advances in medical oncology
Published: May 13, 2025
Assessment of the diagnostic efficacy and clinical significance of [18F]AlF-NOTA-LM3 PET/CT in patients with well-differentiated neuroendocrine tumors.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 27, 2025
Malignant mesothelioma with a novel BAP1 germline frameshift mutation treated with dual immune checkpoint inhibitors: A case report.
Journal: Oncology letters
Published: October 11, 2024
Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review.
Journal: Frontiers in oncology
Published: July 23, 2024
Last Updated: 09/26/2026